<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">2209</journal-id><journal-id journal-id-type="pmc-domain">wjp</journal-id><journal-id journal-id-type="publisher-id">WJP</journal-id><journal-title-group><journal-title>World Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="epub">2220-3206</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11684217</article-id><article-id pub-id-type="pmcid-ver">PMC11684217.1</article-id><article-id pub-id-type="pmcaid">11684217</article-id><article-id pub-id-type="pmcaiid">11684217</article-id><article-id pub-id-type="pmid">39831013</article-id><article-id pub-id-type="doi">10.5498/wjp.v15.i1.100880</article-id><article-id pub-id-type="other">jWJP.v15.i1.eid100880</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Retrospective Study</subject></subj-group></article-categories><title-group><article-title>Correlation analyse between thyroid hormone levels and severity of schizophrenia symptoms</article-title><alt-title>Jiang QH <italic toggle="yes">et al</italic>. TH levels and schizophrenia severity correlation</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="QH">Qi-Hui</given-names></name><aff>Department of Endocrinology and Metabolism, Hengyang Central Hospital, Hengyang 421000, Hunan Province, China</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gong</surname><given-names initials="WD">Wei-Dong</given-names></name><aff>Breast Tumor Surgical Outpatient, Hengyang Central Hospital, Hengyang 421000, Hunan Province, China. <email>18274781070@163.com</email></aff></contrib></contrib-group><author-notes><fn><p>Author contributions: Jiang QH designed the experiments, performed the experiments, and analyzed the data; Gong WD wrote the paper, revised it, and organized the data.</p><p>Corresponding author: Wei-Dong Gong, Breast Tumor Surgical Outpatient, Hengyang Central Hospital, No. 12 Yancheng Road, Hengyang 421000, Hunan Province, China. <email>18274781070@163.com</email></p></fn></author-notes><pub-date pub-type="collection"><day>19</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>19</day><month>1</month><year>2025</year></pub-date><volume>15</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">477964</issue-id><elocation-id>100880</elocation-id><history><date date-type="received"><day>6</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>18</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>18</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-21 17:25:58.730"><day>21</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169;The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/Licenses/by-nc/4.0/</uri></license-p></license></permissions><abstract><sec><title>BACKGROUND</title><p>The imbalance of hormone levels in the body is closely related to the occurrence and progression of schizophrenia, especially thyroid hormones.</p></sec><sec><title>AIM</title><p>To study the relationship between triiodothyronine (T3), thyroxine (T4), free T3 (FT3), free T4 (FT4), thyroid stimulating hormone (TSH) and schizophrenia.</p></sec><sec><title>METHODS</title><p>In this study, 100 schizophrenia patients were selected from our hospital between April 2022 and April 2024. Their clinical data were analyzed retrospectively. Based on the Positive and Negative Syndrome Scale (PANSS) score, patients were divided into mild (1-3 points, <italic toggle="yes">n</italic> = 39), moderate (4 points, <italic toggle="yes">n</italic> = 45), and severe groups (5-7 points, <italic toggle="yes">n</italic> = 16). Additionally, 55 healthy individuals served as a control group. Venous blood samples were collected to measure T3, T4, FT3, FT4, TSH, and cortisol concentrations, analyzing their relationship with PANSS scores.</p></sec><sec><title>RESULTS</title><p>The serum levels of T3, FT3, FT4, TSH and cortisol in the schizophrenia group were lower than those in the control group (<italic toggle="yes">P</italic> &lt; 0.05). With the increase of the severity of the disease, the concentrations of T3 and T4 decreased, while the concentrations of TSH and cortisol increased (<italic toggle="yes">P</italic> &lt; 0.05). The concentrations of TSH and cortisol were positively correlated with the PANSS score, while T3 and T4 were negatively correlated with the PANSS score (<italic toggle="yes">P</italic> &lt; 0.05). The receiver operating characteristic curve results showed that T3, T4, TSH, and cortisol had good efficacy in the diagnosis of schizophrenia. Logistic results showed that decreased T3 level, decreased T4 level, decreased TSH level and increased cortisol level may be independent risk factors for schizophrenia.</p></sec><sec><title>CONCLUSION</title><p>Thyroid hormone levels are associated with the severity of schizophrenia symptoms, which can provide new solutions for the diagnosis and treatment of schizophrenia.</p></sec></abstract><kwd-group><kwd>Thyroid hormone</kwd><kwd>Schizophrenia</kwd><kwd>Symptom severity</kwd><kwd>Positive and Negative Syndrome Scale score</kwd><kwd>Cortisol</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<bold>Core Tip:</bold> Previous studies have confirmed that hormone imbalance is closely related to the occurrence and progression of schizophrenia, especially thyroid hormone. However, the relationship between thyroid hormone and schizophrenia symptoms is still unknown at this stage. Based on this, this study conducted a retrospective analyse to explore the correlation between thyroid hormone levels and the severity of schizophrenia.</p><sec><title>INTRODUCTION</title><p>Schizophrenia is a clinical syndrome whose pathogenesis has not been fully elucidated, it is currently believed to be related to genetic susceptibility genes and environmental factors, the disease affects about 1% of the world&#8217;s population[<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>]. In recent years, the prevalence of schizophrenia has increased year by year, and it is more common in young and middle-aged people. Patients often show cognitive symptoms, negative symptoms and positive symptoms[<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>]. As the disease progresses, about 50% of schizophrenia patients will develop mental disability and then lose their ability to work[<xref rid="B5" ref-type="bibr">5</xref>]. Schizophrenia has a long course and is difficult to cure. After the onset of the disease, patients may be accompanied by hallucinations, confusion, behavioral disorders and other manifestations. In severe cases, they may even harm others or self-harm or commit suicide, which is very harmful and affects social stability[<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>]. Gibson <italic toggle="yes">et al</italic>[<xref rid="B8" ref-type="bibr">8</xref>] pointed out that the imbalance of hormone levels in the body is closely related to the occurrence and progression of schizophrenia, especially thyroid hormones. Thyroid hormones can induce tissue metabolism, promote protein conversion and generate energy in the body, and participate in the regulation of central nervous system development. Excessive increase in their release can enhance nerve excitability, ultimately leading to symptoms such as insomnia and tachycardia[<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>]. Some literature points out that excessive increase in thyroid hormones in the body is related to the risk of suicide in schizophrenia patients, and can directly cause depression or violence, especially triiodothyronine (T3) and thyroxine (T4). Surveys and studies have shown that about 40% of schizophrenia patients have abnormal thyroid function[<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>]. In this way, the role of thyroid hormone levels in schizophrenia is particularly important. However, the relationship between thyroid hormones and schizophrenia symptoms remains unknown at this stage[<xref rid="B13" ref-type="bibr">13</xref>]. Based on this, this study conducted a retrospective analyse to explore the association between thyroid hormone levels and the severity of schizophrenia.</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Study subjects</title><p>Taking thyroid stimulating hormone (TSH) level as the main index, based on previous experience and relevant literature, the standard deviation &#963; is expected to be 4.63, requiring a two-sided test, &#945; is 0.05, and the allowable error &#948; is 1. The sample size is calculated according to the following formula (Figure <xref rid="F1" ref-type="fig">1</xref>). The sample size <italic toggle="yes">n</italic> = 83 can be obtained. Considering the 20% loss to follow-up rate, this study needs to include at least 100 patients as study subjects. In this study, 100 schizophrenia patients were selected from Hengyang Central Hospital as the schizophrenia group between April 2022 and April 2024, and their clinical data were retrieved and retrospectively studied. Another 55 healthy people were selected as the control group.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>
The calculation formula.
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="100880-g001.jpg"/></fig></sec><sec><title>Inclusion and exclusion criteria</title><p>
<bold>Inclusion criteria:</bold> (1) All patients met the relevant diagnostic criteria for schizophrenia[<xref rid="B14" ref-type="bibr">14</xref>]; (2) All patients were diagnosed using magnetic resonance brain structural imaging technology; (3) All patients had complete clinical data available in our hospital; and (4) All patients had normal intellectual development and were first-episode psychosis patients.</p><p>
<bold>Exclusion criteria:</bold> (1) Patients with a history of exposure to psychoactive substances; (2) Patients with a history of drug or alcohol abuse; (3) Patients with a history of electroconvulsive therapy; (4) Patients with brain lesions; and (5) Patients with a history of thyroid dysfunction or treatment with T4.</p></sec><sec><title>Specimen collection</title><p>Venous blood was collected from both the schizophrenia group and the control group in the early morning of the next day after entering the study using sterile vacuum blood collection tubes. After collecting 4-5 mL, the blood was left to stand in a natural state for 30 minutes, and then centrifuged to obtain the supernatant for storage for subsequent testing.</p></sec><sec><title>Thyroid hormone measurement</title><p>AIA-CL2400 fully automatic chemiluminescence immunoassay analyzer (provided by Shanghai Tosoh Biotechnology Co., Ltd.) was used to measure the concentrations of T3, T4, free T3 (FT3), free T4 (FT4), TSH and cortisol in the schizophrenia group and the control group.</p></sec><sec><title>Statistical analysis</title><p>The study data were processed by SPSS 22.0 statistical software. The Shapiro-Wilk method was used to test the normal distribution of the measurement data. The measurement data that met the normal distribution were expressed in the form of (mean &#177; SD). The inter-group comparison was obtained by two-tailed <italic toggle="yes">t</italic> test. The counting data were expressed in the form of [<italic toggle="yes">n</italic> (%)], and the results were obtained by <italic toggle="yes">&#967;</italic><sup>2</sup> test. The receiver operating characteristic curve was used to analyze the diagnostic efficacy of serum T3, T4, FT3, FT4, TSH, and cortisol in schizophrenia. Logistic regression model was used to analyze the independent risk factors affecting schizophrenia. <italic toggle="yes">P</italic> &lt; 0.05 was considered statistically significant.</p></sec></sec><sec><title>RESULTS</title><sec><title>General information</title><p>The final study included 55 healthy subjects and 100 schizophrenia patients. The 100 schizophrenia patients were divided into mild group (1-3 points, <italic toggle="yes">n</italic> = 39), moderate group (4 points, <italic toggle="yes">n</italic> = 45) and severe group (5-7 points, <italic toggle="yes">n</italic> = 16) according to the Positive and Negative Syndrome Scale (PANSS) score. The general data of the subjects included in each group were analyzed, and there was no significant difference in age, gender, and smoking rate among the groups (<italic toggle="yes">P</italic> &gt; 0.05) in Table <xref rid="T1" ref-type="table">1</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>General information</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="2" colspan="1">
<bold>General information</bold>
</td><td rowspan="2" colspan="1">
<bold>Control group (<italic toggle="yes">n</italic> = 55)</bold>
</td><td colspan="3" rowspan="1">
<bold>Schizophrenia group</bold>
<hr/>
</td><td rowspan="2" colspan="1">
<bold>
<italic toggle="yes">t</italic>/<italic toggle="yes">Z</italic></bold>
</td><td rowspan="2" colspan="1">
<bold>
<italic toggle="yes">P</italic> value</bold>
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Mild group (<italic toggle="yes">n</italic> = 39)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Moderate group (<italic toggle="yes">n</italic> = 45)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Severe group (<italic toggle="yes">n</italic> = 16)</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">34.56 &#177; 10.03</td><td rowspan="1" colspan="1">34.28 &#177; 10.67</td><td rowspan="1" colspan="1">34.71 &#177; 10.35</td><td rowspan="1" colspan="1">34.86 &#177; 10.43</td><td rowspan="1" colspan="1">0.018</td><td rowspan="1" colspan="1">0.997</td></tr><tr><td rowspan="1" colspan="1">Gender (male/female)</td><td rowspan="1" colspan="1">25/30</td><td rowspan="1" colspan="1">18/21</td><td rowspan="1" colspan="1">22/23</td><td rowspan="1" colspan="1">6/10</td><td rowspan="1" colspan="1">0.622</td><td rowspan="1" colspan="1">0.891</td></tr><tr><td rowspan="1" colspan="1">Smoking, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">17 (30.91)</td><td rowspan="1" colspan="1">11 (28.21)</td><td rowspan="1" colspan="1">13 (28.89)</td><td rowspan="1" colspan="1">5 (31.25)</td><td rowspan="1" colspan="1">0.113</td><td rowspan="1" colspan="1">0.990</td></tr><tr><td rowspan="1" colspan="1">Drinking, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">4 (7.27)</td><td rowspan="1" colspan="1">5 (12.82)</td><td rowspan="1" colspan="1">4 (8.88)</td><td rowspan="1" colspan="1">1 (6.25)</td><td rowspan="1" colspan="1">1.040</td><td rowspan="1" colspan="1">0.792</td></tr><tr><td rowspan="1" colspan="1">Family history, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">17 (30.91)</td><td rowspan="1" colspan="1">11 (28.21)</td><td rowspan="1" colspan="1">13 (28.89)</td><td rowspan="1" colspan="1">5 (31.25)</td><td rowspan="1" colspan="1">0.113</td><td rowspan="1" colspan="1">0.990</td></tr><tr><td rowspan="1" colspan="1">Marital status, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.772</td><td rowspan="1" colspan="1">0.993</td></tr><tr><td rowspan="1" colspan="1">Unmarried</td><td rowspan="1" colspan="1">16 (29.09)</td><td rowspan="1" colspan="1">12 (30.77)</td><td rowspan="1" colspan="1">13 (28.89)</td><td rowspan="1" colspan="1">4 (25.00)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Married</td><td rowspan="1" colspan="1">30 (54.55)</td><td rowspan="1" colspan="1">20 (51.28)</td><td rowspan="1" colspan="1">23 (51.11)</td><td rowspan="1" colspan="1">8 (50.00)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Divorced/widowed</td><td rowspan="1" colspan="1">9 (16.36)</td><td rowspan="1" colspan="1">7 (17.95)</td><td rowspan="1" colspan="1">9 (20.00)</td><td rowspan="1" colspan="1">4 (25.00)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Years of education (years)</td><td rowspan="1" colspan="1">15.93 &#177; 1.50</td><td rowspan="1" colspan="1">15.97 &#177; 1.27</td><td rowspan="1" colspan="1">15.42 &#177; 1.62</td><td rowspan="1" colspan="1">15.638 &#177; 1.20</td><td rowspan="1" colspan="1">1.380</td><td rowspan="1" colspan="1">0.251</td></tr></tbody></table></table-wrap></sec><sec><title>Thyroid hormone concentrations in schizophrenia group and control group</title><p>The serum T3 (2.04 &#177; 0.53), T4 (118.66 &#177; 17.44), FT3 (4.60 &#177; 0.50), FT4 (16.51 &#177; 2.20), TSH (3.10 &#177; 0.90), and cortisol (3.23 &#177; 0.09) levels in the control group were all within the normal range, but the serum T3 (1.77 &#177; 0.58), T4 (98.78 &#177; 16.30), FT3 (4.35 &#177; 0.60), FT4 (13.40 &#177; 2.19), TSH (2.08 &#177; 0.85), and cortisol (6.50 &#177; 1.30) levels in the schizophrenia group were lower than those in the control group (<italic toggle="yes">P</italic> &lt; 0.05) in Table <xref rid="T2" ref-type="table">2</xref>.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Comparison of thyroid hormone levels (mean &#177; SD)</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Grouping</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>T3 (nmol/L)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>T4 (nmol/L)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>FT3 (pmol/L)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>FT4 (pmol/L)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>TSH (mIU/L)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Cortisol (mmol/L)</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Control group (<italic toggle="yes">n</italic> = 55)</td><td rowspan="1" colspan="1">2.04 &#177; 0.53</td><td rowspan="1" colspan="1">118.66 &#177; 17.44</td><td rowspan="1" colspan="1">4.60 &#177; 0.50</td><td rowspan="1" colspan="1">16.51 &#177; 2.20</td><td rowspan="1" colspan="1">3.10 &#177; 0.90</td><td rowspan="1" colspan="1">3.23 &#177; 0.09</td></tr><tr><td rowspan="1" colspan="1">Schizophrenia group (<italic toggle="yes">n</italic> = 100)</td><td rowspan="1" colspan="1">1.77 &#177; 0.58</td><td rowspan="1" colspan="1">98.78 &#177; 16.30</td><td rowspan="1" colspan="1">4.35 &#177; 0.60</td><td rowspan="1" colspan="1">13.40 &#177; 2.19</td><td rowspan="1" colspan="1">2.08 &#177; 0.85</td><td rowspan="1" colspan="1">6.50 &#177; 1.30</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
</td><td rowspan="1" colspan="1">2.856</td><td rowspan="1" colspan="1">7.086</td><td rowspan="1" colspan="1">2.783</td><td rowspan="1" colspan="1">8.442</td><td rowspan="1" colspan="1">7.002</td><td rowspan="1" colspan="1">25.066</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</td><td rowspan="1" colspan="1">0.005</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">0.006</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr></tbody></table><table-wrap-foot><fn><p>T3: Triiodothyronine; T4: Thyroxine; FT3: Free triiodothyronine; FT4: Free thyroxine; TSH: Thyroid stimulating hormone.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Serum thyroid hormone concentration in patients with different degrees of schizophrenia</title><p>There was no difference in the concentrations of FT3 and FT4 among the mild, moderate and severe groups (<italic toggle="yes">P</italic> &gt; 0.05); however, there were differences in T3, T4, TSH, cortisol and PANSS scores among the three groups. With the increase in the severity of the disease, the concentrations of T3 and T4 decreased, while the concentrations of TSH and cortisol increased (<italic toggle="yes">P</italic> &lt; 0.05) in Table <xref rid="T3" ref-type="table">3</xref>.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Comparison of serum thyroid hormone concentrations in each group (mean &#177; SD)</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Grouping</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>T3 (nmol/L)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>T4 (nmol/L)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>FT3 (pmol/L)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>FT4 (pmol/L)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>TSH (mIU/L)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Cortisol (mmol/L)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>PANSS</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Mild group (<italic toggle="yes">n</italic> = 39)</td><td rowspan="1" colspan="1">1.95 &#177; 0.63</td><td rowspan="1" colspan="1">103.12 &#177; 17.42</td><td rowspan="1" colspan="1">4.29 &#177; 0.52</td><td rowspan="1" colspan="1">13.22 &#177; 1.80</td><td rowspan="1" colspan="1">2.08 &#177; 0.52</td><td rowspan="1" colspan="1">4.95 &#177; 0.88</td><td rowspan="1" colspan="1">68.51 &#177; 5.77</td></tr><tr><td rowspan="1" colspan="1">Moderate group (<italic toggle="yes">n</italic> = 45)</td><td rowspan="1" colspan="1">1.72 &#177; 0.52</td><td rowspan="1" colspan="1">94.13 &#177; 16.11</td><td rowspan="1" colspan="1">4.33 &#177; 0.58</td><td rowspan="1" colspan="1">12.99 &#177; 2.00<xref rid="T3FNa" ref-type="table-fn">a</xref></td><td rowspan="1" colspan="1">2.88 &#177; 0.85<xref rid="T3FNa" ref-type="table-fn">a</xref></td><td rowspan="1" colspan="1">6.32 &#177; 1.25<xref rid="T3FNa" ref-type="table-fn">a</xref></td><td rowspan="1" colspan="1">75.20 &#177; 6.38<xref rid="T3FNa" ref-type="table-fn">a</xref></td></tr><tr><td rowspan="1" colspan="1">Severe group (<italic toggle="yes">n</italic> = 16)</td><td rowspan="1" colspan="1">1.50 &#177; 0.50</td><td rowspan="1" colspan="1">85.23 &#177; 15.20</td><td rowspan="1" colspan="1">4.36 &#177; 0.62</td><td rowspan="1" colspan="1">13.32 &#177; 2.12<xref rid="T3FNa" ref-type="table-fn">a</xref><sup>,</sup><xref rid="T3FNb" ref-type="table-fn">b</xref></td><td rowspan="1" colspan="1">3.41 &#177; 0.99<xref rid="T3FNa" ref-type="table-fn">a</xref><sup>,</sup><xref rid="T3FNb" ref-type="table-fn">b</xref></td><td rowspan="1" colspan="1">7.45 &#177; 1.50<xref rid="T3FNa" ref-type="table-fn">a</xref><sup>,</sup><xref rid="T3FNb" ref-type="table-fn">b</xref></td><td rowspan="1" colspan="1">81.88 &#177; 7.06<xref rid="T3FNa" ref-type="table-fn">a</xref><sup>,</sup><xref rid="T3FNb" ref-type="table-fn">b</xref></td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
</td><td rowspan="1" colspan="1">4.049</td><td rowspan="1" colspan="1">9.615</td><td rowspan="1" colspan="1">0.102</td><td rowspan="1" colspan="1">0.021</td><td rowspan="1" colspan="1">20.721</td><td rowspan="1" colspan="1">29.743</td><td rowspan="1" colspan="1">28.311</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</td><td rowspan="1" colspan="1">0.020</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">0.903</td><td rowspan="1" colspan="1">0.885</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr></tbody></table><table-wrap-foot><fn id="T3FNa"><label>a</label><p>
<italic toggle="yes">P</italic> &lt; 0.05, compared with the mild group.</p></fn><fn id="T3FNb"><label>b</label><p>
<italic toggle="yes">P</italic> &lt; 0.05, compared with the severe group.</p></fn><fn><p>T3: Triiodothyronine; T4: Thyroxine; FT3: Free triiodothyronine; FT4: Free thyroxine; TSH: Thyroid stimulating hormone; PANSS: Positive and Negative Syndrome Scale.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Correlation between thyroid hormone and PANSS score</title><p>Pearson correlation analyse of the correlation between thyroid hormone and PANSS score showed that the concentrations of FT3 and FT4 were not related to PANSS score (<italic toggle="yes">P</italic> &gt; 0.05); TSH and cortisol concentrations were positively correlated with PANSS score, while T3 and T4 were negatively correlated with PANSS score (<italic toggle="yes">P</italic> &lt; 0.05) in Table <xref rid="T4" ref-type="table">4</xref>.</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Correlation between thyroid hormone and Positive and Negative Syndrome Scale score</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="2" colspan="1">
<bold>Thyroid hormone</bold>
</td><td colspan="2" rowspan="1">
<bold>PANSS score</bold>
<hr/>
</td></tr><tr><td rowspan="1" colspan="1">
<bold>
<italic toggle="yes">r</italic>
</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic> value</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">T3</td><td rowspan="1" colspan="1">-0.259</td><td rowspan="1" colspan="1">0.025</td></tr><tr><td rowspan="1" colspan="1">T4</td><td rowspan="1" colspan="1">-0.218</td><td rowspan="1" colspan="1">0.029</td></tr><tr><td rowspan="1" colspan="1">FT3</td><td rowspan="1" colspan="1">0.130</td><td rowspan="1" colspan="1">0.196</td></tr><tr><td rowspan="1" colspan="1">FT4</td><td rowspan="1" colspan="1">-0.049</td><td rowspan="1" colspan="1">0.631</td></tr><tr><td rowspan="1" colspan="1">TSH</td><td rowspan="1" colspan="1">0.215</td><td rowspan="1" colspan="1">0.032</td></tr><tr><td rowspan="1" colspan="1">FSH</td><td rowspan="1" colspan="1">0.315</td><td rowspan="1" colspan="1">0.019</td></tr></tbody></table><table-wrap-foot><fn><p>T3: Triiodothyronine; T4: Thyroxine; FT3: Free triiodothyronine; FT4: Free thyroxine; TSH: Thyroid stimulating hormone; FSH: Follicle-stimulating hormone; PANSS: Positive and Negative Syndrome Scale.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Receiver operating characteristic curve analyse of related factors</title><p>The area under the curve of T3, T4, FT3, FT4, TSH, and cortisol were 0.749, 0.766, 0.545, 0.547, 0.890, 0.925, respectively. The optimal cutoff values were 1.68 nmol/L, 98.82 nmol/L, 4.49 pmol/L, 13.86 pmol/L, and 2.74 mIU/L, 5.88 mmol/L respectively. The sensitivities were 75.0%, 87.5%, 50.00%, 62.5%, 81.2%, and 81.2%, respectively. The specificities were 74.36%, 56.4%, 74.36%, 66.7%, 89.7%, and 89.7%, respectively. Among them, T3, T4, TSH, and cortisol had good efficacy in the diagnosis of schizophrenia in Table <xref rid="T5" ref-type="table">5</xref> and Figure <xref rid="F2" ref-type="fig">2</xref>.</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p>
<bold>Receiver operating characteristic curve analyse of relevant factors.</bold> T3: Triiodothyronine; T4: Thyroxine; FT3: Free triiodothyronine; FT4: Free thyroxine; TSH: Thyroid stimulating hormone.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="100880-g002.jpg"/></fig><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><p>Receiver operating characteristic curve analyse of related factors</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Index</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>AUC</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>SE</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>95%CI</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic> value</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Optimal cutoff value</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Sensitivity (%)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Specificity (%)</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">T3</td><td rowspan="1" colspan="1">0.749</td><td rowspan="1" colspan="1">0.071</td><td rowspan="1" colspan="1">0.614-0.856</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">&#8804; 1.68</td><td rowspan="1" colspan="1">75.0</td><td rowspan="1" colspan="1">74.4</td></tr><tr><td rowspan="1" colspan="1">T4</td><td rowspan="1" colspan="1">0.766</td><td rowspan="1" colspan="1">0.070</td><td rowspan="1" colspan="1">0.632-0.870</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">&#8804; 98.82</td><td rowspan="1" colspan="1">87.5</td><td rowspan="1" colspan="1">56.4</td></tr><tr><td rowspan="1" colspan="1">FT3</td><td rowspan="1" colspan="1">0.545</td><td rowspan="1" colspan="1">0.093</td><td rowspan="1" colspan="1">0.405-0.680</td><td rowspan="1" colspan="1">0.628</td><td rowspan="1" colspan="1">&gt; 4.49</td><td rowspan="1" colspan="1">50.0</td><td rowspan="1" colspan="1">74.36</td></tr><tr><td rowspan="1" colspan="1">FT4</td><td rowspan="1" colspan="1">0.547</td><td rowspan="1" colspan="1">0.092</td><td rowspan="1" colspan="1">0.407-0.682</td><td rowspan="1" colspan="1">0.608</td><td rowspan="1" colspan="1">&gt; 13.86</td><td rowspan="1" colspan="1">62.5</td><td rowspan="1" colspan="1">66.7</td></tr><tr><td rowspan="1" colspan="1">TSH</td><td rowspan="1" colspan="1">0.890</td><td rowspan="1" colspan="1">0.051</td><td rowspan="1" colspan="1">0.777</td><td rowspan="1" colspan="1">0.958</td><td rowspan="1" colspan="1">&gt; 2.74</td><td rowspan="1" colspan="1">81.2</td><td rowspan="1" colspan="1">89.7</td></tr><tr><td rowspan="1" colspan="1">Cortisol</td><td rowspan="1" colspan="1">0.925</td><td rowspan="1" colspan="1">0.038</td><td rowspan="1" colspan="1">0.821-0.978</td><td rowspan="1" colspan="1">&lt; 0.001</td><td rowspan="1" colspan="1">&gt; 5.88</td><td rowspan="1" colspan="1">81.3</td><td rowspan="1" colspan="1">89.7</td></tr></tbody></table><table-wrap-foot><fn><p>T3: Triiodothyronine; T4: Thyroxine; FT3: Free triiodothyronine; FT4: Free thyroxine; TSH: Thyroid stimulating hormone; AUC: Area under the curve; CI: Confidence interval.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Logistic multivariate analyse of factors affecting schizophrenia</title><p>T3, T4, FT3, FT4, and TSH in the Logistic regression model, it was found that decreased T3 levels [&#946; = 0.616, odds ratio (OR) = 1.852, 95% confidence interval (CI): 1.526-2.652], decreased T4 levels (&#946; = 0.506, OR = 1.658, 95%CI: 1.121-1.985), decreased TSH levels (&#946; = 0.699, OR = 2.011, 95%CI: 1.781-2.698) and Increased cortisol levels (&#946; = 0.511, OR = 1.523, 95%CI: 1.132-2.011) can all be used as independent risk factors for schizophrenia (Tables <xref rid="T6" ref-type="table">6</xref> and <xref rid="T7" ref-type="table">7</xref>).</p><table-wrap position="float" id="T6" orientation="portrait"><label>Table 6</label><caption><p>Value assignment of relevant factors</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Factor</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Assignment</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">T3</td><td rowspan="1" colspan="1">1: &#8804; 1.68 nmol/L, 0: &gt; 1.68 nmol/L</td></tr><tr><td rowspan="1" colspan="1">T4</td><td rowspan="1" colspan="1">1: &#8804; 98.82 nmol/L, 0: &gt; 98.82 nmol/L</td></tr><tr><td rowspan="1" colspan="1">FT3</td><td rowspan="1" colspan="1">1: &#8804; 4.49 pmol/L, 0: &gt; 4.49 pmol/L</td></tr><tr><td rowspan="1" colspan="1">FT4</td><td rowspan="1" colspan="1">1: &#8804; 13.86 pmol/L, 0: &gt; 13.86 pmol/L</td></tr><tr><td rowspan="1" colspan="1">TSH</td><td rowspan="1" colspan="1">1: &#8804; 2.74 mIU/L, 0: &gt; 2.74 mIU/L</td></tr><tr><td rowspan="1" colspan="1">Cortisol</td><td rowspan="1" colspan="1">1: &gt; 5.88 mmol, 0: &#8804; 5.88 mmol</td></tr></tbody></table><table-wrap-foot><fn><p>T3: Triiodothyronine; T4: Thyroxine; FT3: Free triiodothyronine; FT4: Free thyroxine; TSH: Thyroid stimulating hormone.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T7" orientation="portrait"><label>Table 7</label><caption><p>Logistic multivariate analyse of factors affecting schizophrenia</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Index</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>&#946;</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>SE</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Wald</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>OR (95%CI)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic> value</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">T3</td><td rowspan="1" colspan="1">-0.616</td><td rowspan="1" colspan="1">0.245</td><td rowspan="1" colspan="1">10.262</td><td rowspan="1" colspan="1">1.852 (1.526-2.652)</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">T4</td><td rowspan="1" colspan="1">-0.506</td><td rowspan="1" colspan="1">0.219</td><td rowspan="1" colspan="1">10.550</td><td rowspan="1" colspan="1">1.658 (1.121-1.985)</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">FT3</td><td rowspan="1" colspan="1">-0.227</td><td rowspan="1" colspan="1">0.277</td><td rowspan="1" colspan="1">2.958</td><td rowspan="1" colspan="1">1.255 (1.026-1.451)</td><td rowspan="1" colspan="1">0.152</td></tr><tr><td rowspan="1" colspan="1">FT4</td><td rowspan="1" colspan="1">-0.264</td><td rowspan="1" colspan="1">0.241</td><td rowspan="1" colspan="1">4.545</td><td rowspan="1" colspan="1">1.302 (1.114-1.534)</td><td rowspan="1" colspan="1">0.089</td></tr><tr><td rowspan="1" colspan="1">TSH</td><td rowspan="1" colspan="1">-0.699</td><td rowspan="1" colspan="1">0.271</td><td rowspan="1" colspan="1">9.518</td><td rowspan="1" colspan="1">2.011 (1.781-2.698)</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr><tr><td rowspan="1" colspan="1">Cortisol</td><td rowspan="1" colspan="1">0.511</td><td rowspan="1" colspan="1">0.230</td><td rowspan="1" colspan="1">9.825</td><td rowspan="1" colspan="1">1.523 (1.132-2.011)</td><td rowspan="1" colspan="1">&lt; 0.001</td></tr></tbody></table><table-wrap-foot><fn><p>T3: Triiodothyronine; T4: Thyroxine; FT3: Free triiodothyronine; FT4: Free thyroxine; TSH: Thyroid stimulating hormone; OR: Odds ratio; CI: Confidence interval.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec><title>DISCUSSION</title><p>Schizophrenia is a mental illness of unknown etiology. Brain structural lesions and neurological damage can lead to dysregulation of neurotransmitter release, inducing clinical symptoms such as apathy, delusions, and agitation. Some patients improve or recover after formal management intervention[<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>]; however, in most cases, patients have a very high risk of relapse after improvement, so long-term management intervention is still needed after improvement[<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B19" ref-type="bibr">19</xref>]. Sharif <italic toggle="yes">et al</italic>[<xref rid="B20" ref-type="bibr">20</xref>] used multivariate analyse to evaluate the relationship between schizophrenia symptoms and thyroid function and observed that schizophrenia patients were closely related to hypothyroidism. Gyllenberg <italic toggle="yes">et al</italic>[<xref rid="B21" ref-type="bibr">21</xref>] prospectively observed that hypothyroidism in pregnant women in the early and middle stages of pregnancy can significantly increase their risk of schizophrenia. In this case, the translation information provided by the mother can cause the offspring molecules and cells to deviate. In recent years, the incidence of schizophrenia has been increasing, so in-depth explanation of the relationship between the occurrence of this disease and thyroid hormone has gradually become a hot topic. This study observed that the serum T3, T4, FT3, FT4, TSH, and cortisol concentrations of the control group were all within the normal range, but the serum T3, T4, FT3, FT4, TSH, and cortisol concentrations of the schizophrenia group were lower than those of the control group. The results of this study indicate that thyroid function abnormalities occur in patients with schizophrenia accompanied by abnormal thyroid hormone concentrations. Accompanied by dysfunction of thalamocortical circuits. PANSS score is an important criterion for measuring the severity of schizophrenia. Therefore, this study grouped schizophrenia patients according to PANSS score and observed that there was no difference in FT3 and FT4 concentrations among the mild, moderate and severe groups, there were differences in T3, T4, TSH, cortisol, and PANSS scores among the three groups. With the increase in the severity of the disease, the concentrations of T3 and T4 decreased, while the concentrations of TSH and cortisol increased, indicating that T3, T4, TSH, and cortisol concentrations are closely related to the severity of symptoms in patients with schizophrenia. This may be because patients with this disease usually have abnormal brain metabolism. If their brain vascular resistance increases, it can reduce brain blood flow, leading to cerebral ischemia, hypoxia, <italic toggle="yes">etc.</italic>, and ultimately have an adverse effect on thyroid function[<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B23" ref-type="bibr">23</xref>]. In addition, patients with this disease have a large release of neurotransmitters such as dopamine in their brains, which can cause abnormal release of central neurotransmitters, endocrine system internal environment disorders, hinder the release of thyroid hormones, and thus affect the patient&#8217;s mood and cognitive function, ultimately leading to the occurrence of schizophrenia[<xref rid="B24" ref-type="bibr">24</xref>-<xref rid="B28" ref-type="bibr">28</xref>]. Huang <italic toggle="yes">et al</italic>[<xref rid="B29" ref-type="bibr">29</xref>] measured the serum concentration of 916 patients with schizophrenia and observed that the T3 concentration was reduced, which is also a population-specific risk factor for coronary artery calcification in schizophrenia. In addition, there is a mutually regulatory relationship between thyroid hormones and cortisol. High levels of cortisol may inhibit the synthesis and secretion of thyroid hormones, while changes in thyroid hormones may affect the secretion of cortisol. This interaction may play an important role in the pathological mechanism of schizophrenia. Studies have shown that thyroid hormones may affect the secretion of cortisol by regulating the hypothalamic-pituitary-adrenal axis. Conversely, elevated cortisol may further aggravate the symptoms of schizophrenia by affecting thyroid function[<xref rid="B30" ref-type="bibr">30</xref>]. Freuer and Meisinger[<xref rid="B13" ref-type="bibr">13</xref>] conducted a two-way two-sample Mendelian randomization experiment to explore the relationship between thyroid function and schizophrenia and found that increased TSH concentration can reduce the incidence of schizophrenia. However, Li <italic toggle="yes">et al</italic>[<xref rid="B11" ref-type="bibr">11</xref>] analyzed the serum FT3 and FT4 concentrations of 75 healthy subjects and 154 schizophrenia patients and found that the serum index concentrations of schizophrenia patients were reduced, and the FT3 and FT4 concentrations of patients with agitated behavior were even lower. In this study, the correlation between thyroid hormone and PANSS score was analyzed by Pearson correlation. It was observed that FT3 and FT4 concentrations were not related to PANSS score (<italic toggle="yes">P</italic> &gt; 0.05); however, T3, T4, and TSH concentrations were positively correlated with PANSS score (<italic toggle="yes">P</italic> &lt; 0.05), suggesting that thyroid hormone concentrations are associated with the severity of symptoms in patients with schizophrenia. This is due to the interaction between the brain and thyroid function, in which the brain can participate in regulating the release of thyroid hormones, and the thyroid can also negatively feedback to the brain. In addition, thyroid function can also be affected by psychological factors and emotions, so there is a certain correlation between the two[<xref rid="B31" ref-type="bibr">31</xref>-<xref rid="B35" ref-type="bibr">35</xref>]. This study also observed that the area under the curves of T3, T4, FT3, FT4, and TSH were 0.749, 0.766, 0.545, 0.547, and 0.890, respectively, and the optimal cutoff values were 1.68 nmol/L, 98.82 nmol/L, 4.49 pmol/L, 13.86 pmol/L, and 2.74 mIU/L, respectively, with sensitivities of 75.0%, 87.5%, 50.00%, 62.5%, and 81.2%, and specificities of 74.36%, 56.4%, 74.36%, 66.7%, and 89.7%, respectively. Among them, T3, T4, and TSH have good efficacy in the diagnosis of schizophrenia. And by incorporating T3, T4, FT3, FT4, and TSH into the Logistic regression model, it was found that decreased T3 levels, decreased T4 levels, and decreased TSH levels can all serve as independent risk factors affecting schizophrenia. Therefore, it is necessary to pay attention to the above risk factors.</p></sec><sec><title>CONCLUSION</title><p>Thyroid hormone levels are associated with the severity of schizophrenia symptoms, which can provide new solutions for the diagnosis and treatment of schizophrenia. The measurement of thyroid hormone levels can help doctors better understand the patient&#8217;s disease status and provide more targeted personalized treatment strategies for patients. Further study is needed on the pathological mechanism between abnormal thyroid function and schizophrenia in the future.</p></sec></body><back><fn-group><fn><p>
<bold>Institutional review board statement:</bold> The study was reviewed and approved by the Hengyang Central Hospital Institutional Review Board.</p></fn><fn><p>
<bold>Informed consent statement:</bold> All study participants, or their legal guardian, provided informed written consent prior to study enrollment.</p></fn><fn fn-type="COI-statement"><p>
<bold>Conflict-of-interest statement:</bold> All the authors report no relevant conflicts of interest for this article.</p></fn><fn><p>
<bold>Provenance and peer review:</bold> Unsolicited article; Externally peer reviewed.</p></fn><fn><p>
<bold>Peer-review model:</bold> Single blind</p></fn><fn><p>
<bold>Specialty type:</bold> Psychiatry</p></fn><fn><p>
<bold>Country of origin:</bold> China</p></fn><fn><p>
<bold>Peer-review report&#8217;s classification</bold>
</p></fn><fn><p>
<bold>Scientific Quality:</bold> Grade B, Grade C</p></fn><fn><p>
<bold>Novelty:</bold> Grade B, Grade C</p></fn><fn><p>
<bold>Creativity or Innovation:</bold> Grade B, Grade C</p></fn><fn><p>
<bold>Scientific Significance:</bold> Grade B, Grade C</p></fn><fn><p>
<bold>P-Reviewer:</bold> Khalifeh H; Romm KF <bold>S-Editor:</bold> Wang JJ <bold>L-Editor:</bold> A <bold>P-Editor:</bold> Wang WB</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCutcheon</surname><given-names>RA</given-names></name><name name-style="western"><surname>Reis</surname><given-names>Marques T</given-names></name><name name-style="western"><surname>Howes</surname><given-names>OD</given-names></name></person-group><article-title>Schizophrenia-An Overview</article-title><source>JAMA Psychiatry</source><year>2020</year><volume>77</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">31664453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2019.3360</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>CC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lane</surname><given-names>HY</given-names></name></person-group><article-title>Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>9718</fpage><pub-id pub-id-type="pmid">34575878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22189718</pub-id><pub-id pub-id-type="pmcid">PMC8466274</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorillo</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuomo</surname><given-names>A</given-names></name><name name-style="western"><surname>Sampogna</surname><given-names>G</given-names></name><name name-style="western"><surname>Albert</surname><given-names>U</given-names></name><name name-style="western"><surname>Cal&#242;</surname><given-names>P</given-names></name><name name-style="western"><surname>Cerveri</surname><given-names>G</given-names></name><name name-style="western"><surname>De</surname><given-names>Filippis S</given-names></name><name name-style="western"><surname>Masi</surname><given-names>G</given-names></name><name name-style="western"><surname>Pompili</surname><given-names>M</given-names></name><name name-style="western"><surname>Serafini</surname><given-names>G</given-names></name><name name-style="western"><surname>Vita</surname><given-names>A</given-names></name><name name-style="western"><surname>Zuddas</surname><given-names>A</given-names></name><name name-style="western"><surname>Fagiolini</surname><given-names>A</given-names></name></person-group><article-title>Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice</article-title><source>Expert Opin Pharmacother</source><year>2022</year><volume>23</volume><fpage>1801</fpage><lpage>1818</lpage><pub-id pub-id-type="pmid">36398838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14656566.2022.2141568</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guarro</surname><given-names>Carreras MT</given-names></name><name name-style="western"><surname>Jim&#233;nez</surname><given-names>Su&#225;rez L</given-names></name><name name-style="western"><surname>Lago</surname><given-names>Garc&#237;a L</given-names></name><name name-style="western"><surname>Montes</surname><given-names>Reula L</given-names></name><name name-style="western"><surname>Neyra</surname><given-names>Del Rosario A</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>Batista FA</given-names></name><name name-style="western"><surname>Velasco</surname><given-names>Santos M</given-names></name><name name-style="western"><surname>Prados-Ojeda</surname><given-names>JL</given-names></name><name name-style="western"><surname>Diaz-Mars&#224;</surname><given-names>M</given-names></name><name name-style="western"><surname>Mart&#237;n-Carrasco</surname><given-names>M</given-names></name><name name-style="western"><surname>Cardenas</surname><given-names>A</given-names></name></person-group><article-title>Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive, and cognitive symptoms in schizophrenia and of dual psychosis</article-title><source>Drugs Context</source><year>2024</year><volume>13</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.7573/dic.2024-4-4</pub-id><pub-id pub-id-type="pmcid">PMC11313206</pub-id><pub-id pub-id-type="pmid">39131604</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solmi</surname><given-names>M</given-names></name><name name-style="western"><surname>Seitidis</surname><given-names>G</given-names></name><name name-style="western"><surname>Mavridis</surname><given-names>D</given-names></name><name name-style="western"><surname>Correll</surname><given-names>CU</given-names></name><name name-style="western"><surname>Dragioti</surname><given-names>E</given-names></name><name name-style="western"><surname>Guimond</surname><given-names>S</given-names></name><name name-style="western"><surname>Tuominen</surname><given-names>L</given-names></name><name name-style="western"><surname>Darg&#233;l</surname><given-names>A</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>AF</given-names></name><name name-style="western"><surname>Fornaro</surname><given-names>M</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M</given-names></name><name name-style="western"><surname>Monaco</surname><given-names>F</given-names></name><name name-style="western"><surname>Song</surname><given-names>M</given-names></name><name name-style="western"><surname>Il</surname><given-names>Shin J</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>S</given-names></name></person-group><article-title>Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019</article-title><source>Mol Psychiatry</source><year>2023</year><volume>28</volume><fpage>5319</fpage><lpage>5327</lpage><pub-id pub-id-type="pmid">37500825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-023-02138-4</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabe</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Perez</surname><given-names>N</given-names></name><name name-style="western"><surname>Solmi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mucci</surname><given-names>A</given-names></name><name name-style="western"><surname>Galderisi</surname><given-names>S</given-names></name><name name-style="western"><surname>Strauss</surname><given-names>GP</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>S</given-names></name></person-group><article-title>Thirty years of research on negative symptoms of schizophrenia: A scientometric analysis of hotspots, bursts, and research trends</article-title><source>Neurosci Biobehav Rev</source><year>2023</year><volume>144</volume><fpage>104979</fpage><pub-id pub-id-type="pmid">36463972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2022.104979</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuo</surname><given-names>C</given-names></name><name name-style="western"><surname>Fang</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name><name name-style="western"><surname>Ping</surname><given-names>J</given-names></name></person-group><article-title>Brain imaging features in schizophrenia with co-occurring auditory verbal hallucinations and depressive symptoms-Implication for novel therapeutic strategies to alleviate the reciprocal deterioration</article-title><source>Brain Behav</source><year>2021</year><volume>11</volume><fpage>e01991</fpage><pub-id pub-id-type="pmid">33305913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/brb3.1991</pub-id><pub-id pub-id-type="pmcid">PMC7882177</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jasuja</surname><given-names>GK</given-names></name><name name-style="western"><surname>Self</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Seal</surname><given-names>KH</given-names></name><name name-style="western"><surname>Byers</surname><given-names>AL</given-names></name></person-group><article-title>Menopausal Hormone Therapy and Suicide in a National Sample of Midlife and Older Women Veterans</article-title><source>Med Care</source><year>2021</year><volume>59</volume><fpage>S70</fpage><lpage>S76</lpage><pub-id pub-id-type="pmid">33438886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MLR.0000000000001433</pub-id><pub-id pub-id-type="pmcid">PMC8504206</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawicka-Gutaj</surname><given-names>N</given-names></name><name name-style="western"><surname>Zawalna</surname><given-names>N</given-names></name><name name-style="western"><surname>Gut</surname><given-names>P</given-names></name><name name-style="western"><surname>Rucha&#322;a</surname><given-names>M</given-names></name></person-group><article-title>Relationship between thyroid hormones and central nervous system metabolism in physiological and pathological conditions</article-title><source>Pharmacol Rep</source><year>2022</year><volume>74</volume><fpage>847</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">35771431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s43440-022-00377-w</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pagnin</surname><given-names>M</given-names></name><name name-style="western"><surname>Kondos-Devcic</surname><given-names>D</given-names></name><name name-style="western"><surname>Chincarini</surname><given-names>G</given-names></name><name name-style="western"><surname>Cumberland</surname><given-names>A</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Tolcos</surname><given-names>M</given-names></name></person-group><article-title>Role of thyroid hormones in normal and abnormal central nervous system myelination in humans and rodents</article-title><source>Front Neuroendocrinol</source><year>2021</year><volume>61</volume><fpage>100901</fpage><pub-id pub-id-type="pmid">33493504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yfrne.2021.100901</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J</given-names></name><name name-style="western"><surname>Niu</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Associations of C-Reactive Protein, Free Triiodothyronine, Thyroid Stimulating Hormone and Creatinine Levels with Agitation in Patients with Schizophrenia: A Comparative Cross-Sectional Study</article-title><source>Neuropsychiatr Dis Treat</source><year>2021</year><volume>17</volume><fpage>2575</fpage><lpage>2585</lpage><pub-id pub-id-type="pmid">34408419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S322005</pub-id><pub-id pub-id-type="pmcid">PMC8364367</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>AL</given-names></name><name name-style="western"><surname>Mowry</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Pender</surname><given-names>MP</given-names></name><name name-style="western"><surname>Greer</surname><given-names>JM</given-names></name></person-group><article-title>Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?</article-title><source>Immunol Cell Biol</source><year>2005</year><volume>83</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">15661036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1440-1711.2005.01305.x</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freuer</surname><given-names>D</given-names></name><name name-style="western"><surname>Meisinger</surname><given-names>C</given-names></name></person-group><article-title>Causal link between thyroid function and schizophrenia: a two-sample Mendelian randomization study</article-title><source>Eur J Epidemiol</source><year>2023</year><volume>38</volume><fpage>1081</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">37589836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-023-01034-z</pub-id><pub-id pub-id-type="pmcid">PMC10570193</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tandon</surname><given-names>R</given-names></name><name name-style="western"><surname>Gaebel</surname><given-names>W</given-names></name><name name-style="western"><surname>Barch</surname><given-names>DM</given-names></name><name name-style="western"><surname>Bustillo</surname><given-names>J</given-names></name><name name-style="western"><surname>Gur</surname><given-names>RE</given-names></name><name name-style="western"><surname>Heckers</surname><given-names>S</given-names></name><name name-style="western"><surname>Malaspina</surname><given-names>D</given-names></name><name name-style="western"><surname>Owen</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>S</given-names></name><name name-style="western"><surname>Tsuang</surname><given-names>M</given-names></name><name name-style="western"><surname>Van</surname><given-names>Os J</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>W</given-names></name></person-group><article-title>Definition and description of schizophrenia in the DSM-5</article-title><source>Schizophr Res</source><year>2013</year><volume>150</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">23800613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.schres.2013.05.028</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krystal</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kane</surname><given-names>JM</given-names></name><name name-style="western"><surname>Correll</surname><given-names>CU</given-names></name><name name-style="western"><surname>Walling</surname><given-names>DP</given-names></name><name name-style="western"><surname>Leoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Duvvuri</surname><given-names>S</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>I</given-names></name><name name-style="western"><surname>Iredale</surname><given-names>P</given-names></name><name name-style="western"><surname>Frohlich</surname><given-names>L</given-names></name><name name-style="western"><surname>Versavel</surname><given-names>S</given-names></name><name name-style="western"><surname>Perry</surname><given-names>P</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>R</given-names></name><name name-style="western"><surname>Renger</surname><given-names>J</given-names></name></person-group><article-title>Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial</article-title><source>Lancet</source><year>2022</year><volume>400</volume><fpage>2210</fpage><lpage>2220</lpage><pub-id pub-id-type="pmid">36528376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(22)01990-0</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabe</surname><given-names>M</given-names></name><name name-style="western"><surname>Pillinger</surname><given-names>T</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Taipale</surname><given-names>H</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>A</given-names></name><name name-style="western"><surname>Tiihonen</surname><given-names>J</given-names></name><name name-style="western"><surname>Leucht</surname><given-names>S</given-names></name><name name-style="western"><surname>Correll</surname><given-names>CU</given-names></name><name name-style="western"><surname>Solmi</surname><given-names>M</given-names></name></person-group><article-title>Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends</article-title><source>Neurosci Biobehav Rev</source><year>2022</year><volume>136</volume><fpage>104608</fpage><pub-id pub-id-type="pmid">35303594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2022.104608</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solmi</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Daure</surname><given-names>C</given-names></name><name name-style="western"><surname>Buot</surname><given-names>A</given-names></name><name name-style="western"><surname>Ljuslin</surname><given-names>M</given-names></name><name name-style="western"><surname>Verroust</surname><given-names>V</given-names></name><name name-style="western"><surname>Mallet</surname><given-names>L</given-names></name><name name-style="western"><surname>Khazaal</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rothen</surname><given-names>S</given-names></name><name name-style="western"><surname>Thorens</surname><given-names>G</given-names></name><name name-style="western"><surname>Zullino</surname><given-names>D</given-names></name><name name-style="western"><surname>Gobbi</surname><given-names>G</given-names></name><name name-style="western"><surname>Rosenblat</surname><given-names>J</given-names></name><name name-style="western"><surname>Husain</surname><given-names>MI</given-names></name><name name-style="western"><surname>De</surname><given-names>Gregorio D</given-names></name><name name-style="western"><surname>Castle</surname><given-names>D</given-names></name><name name-style="western"><surname>Sab&#233;</surname><given-names>M</given-names></name></person-group><article-title>A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs</article-title><source>Eur Neuropsychopharmacol</source><year>2022</year><volume>64</volume><fpage>44</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">36191546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euroneuro.2022.09.004</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campeau</surname><given-names>A</given-names></name><name name-style="western"><surname>Mills</surname><given-names>RH</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>T</given-names></name><name name-style="western"><surname>Rossitto</surname><given-names>LA</given-names></name><name name-style="western"><surname>Meehan</surname><given-names>M</given-names></name><name name-style="western"><surname>Dorrestein</surname><given-names>P</given-names></name><name name-style="western"><surname>Daly</surname><given-names>R</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TT</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Jeste</surname><given-names>DV</given-names></name><name name-style="western"><surname>Hook</surname><given-names>V</given-names></name></person-group><article-title>Multi-omics of human plasma reveals molecular features of dysregulated inflammation and accelerated aging in schizophrenia</article-title><source>Mol Psychiatry</source><year>2022</year><volume>27</volume><fpage>1217</fpage><lpage>1225</lpage><pub-id pub-id-type="pmid">34741130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-021-01339-z</pub-id><pub-id pub-id-type="pmcid">PMC9054664</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharaev</surname><given-names>MG</given-names></name><name name-style="western"><surname>Malashenkova</surname><given-names>IK</given-names></name><name name-style="western"><surname>Maslennikova</surname><given-names>AV</given-names></name><name name-style="western"><surname>Zakharova</surname><given-names>NV</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>AV</given-names></name><name name-style="western"><surname>Burnaev</surname><given-names>EV</given-names></name><name name-style="western"><surname>Mamedova</surname><given-names>GS</given-names></name><name name-style="western"><surname>Krynskiy</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ogurtsov</surname><given-names>DP</given-names></name><name name-style="western"><surname>Kondrateva</surname><given-names>EA</given-names></name><name name-style="western"><surname>Druzhinina</surname><given-names>PV</given-names></name><name name-style="western"><surname>Zubrikhina</surname><given-names>MO</given-names></name><name name-style="western"><surname>Arkhipov</surname><given-names>AY</given-names></name><name name-style="western"><surname>Strelets</surname><given-names>VB</given-names></name><name name-style="western"><surname>Ushakov</surname><given-names>VL</given-names></name></person-group><article-title>Diagnosis of Schizophrenia Based on the Data of Various Modalities: Biomarkers and Machine Learning Techniques (Review)</article-title><source>Sovrem Tekhnologii Med</source><year>2022</year><volume>14</volume><fpage>53</fpage><lpage>75</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.17691/stm2022.14.5.06</pub-id><pub-id pub-id-type="pmcid">PMC10171060</pub-id><pub-id pub-id-type="pmid">37181835</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharif</surname><given-names>K</given-names></name><name name-style="western"><surname>Tiosano</surname><given-names>S</given-names></name><name name-style="western"><surname>Watad</surname><given-names>A</given-names></name><name name-style="western"><surname>Comaneshter</surname><given-names>D</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AD</given-names></name><name name-style="western"><surname>Shoenfeld</surname><given-names>Y</given-names></name><name name-style="western"><surname>Amital</surname><given-names>H</given-names></name></person-group><article-title>The link between schizophrenia and hypothyroidism: a population-based study</article-title><source>Immunol Res</source><year>2018</year><volume>66</volume><fpage>663</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">30350120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-018-9030-7</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gyllenberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Sourander</surname><given-names>A</given-names></name><name name-style="western"><surname>Surcel</surname><given-names>HM</given-names></name><name name-style="western"><surname>Hinkka-Yli-Salom&#228;ki</surname><given-names>S</given-names></name><name name-style="western"><surname>McKeague</surname><given-names>IW</given-names></name><name name-style="western"><surname>Brown</surname><given-names>AS</given-names></name></person-group><article-title>Hypothyroxinemia During Gestation and Offspring Schizophrenia in a National Birth Cohort</article-title><source>Biol Psychiatry</source><year>2016</year><volume>79</volume><fpage>962</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">26194598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2015.06.014</pub-id><pub-id pub-id-type="pmcid">PMC4684794</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kornetova</surname><given-names>EG</given-names></name><name name-style="western"><surname>Kornetov</surname><given-names>AN</given-names></name><name name-style="western"><surname>Mednova</surname><given-names>IA</given-names></name><name name-style="western"><surname>Lobacheva</surname><given-names>OA</given-names></name><name name-style="western"><surname>Gerasimova</surname><given-names>VI</given-names></name><name name-style="western"><surname>Dubrovskaya</surname><given-names>VV</given-names></name><name name-style="western"><surname>Tolmachev</surname><given-names>IV</given-names></name><name name-style="western"><surname>Semke</surname><given-names>AV</given-names></name><name name-style="western"><surname>Loonen</surname><given-names>AJM</given-names></name><name name-style="western"><surname>Bokhan</surname><given-names>NA</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>SA</given-names></name></person-group><article-title>Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome</article-title><source>Diagnostics (Basel)</source><year>2020</year><volume>10</volume><fpage>683</fpage><pub-id pub-id-type="pmid">32927785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics10090683</pub-id><pub-id pub-id-type="pmcid">PMC7554913</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Song</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wei</surname><given-names>N</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Yi</surname><given-names>W</given-names></name><name name-style="western"><surname>Pan</surname><given-names>R</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Su</surname><given-names>H</given-names></name></person-group><article-title>Impaired thyroid hormone sensitivity exacerbates the effect of PM(2.5) and its components on dyslipidemia in schizophrenia</article-title><source>Sci Total Environ</source><year>2024</year><volume>945</volume><fpage>174055</fpage><pub-id pub-id-type="pmid">38889814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scitotenv.2024.174055</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makarow-Gronert</surname><given-names>A</given-names></name><name name-style="western"><surname>Margulska</surname><given-names>A</given-names></name><name name-style="western"><surname>Strzelecki</surname><given-names>D</given-names></name><name name-style="western"><surname>Krajewska</surname><given-names>K</given-names></name><name name-style="western"><surname>Gmitrowicz</surname><given-names>A</given-names></name><name name-style="western"><surname>Gawlik-Kotelnicka</surname><given-names>O</given-names></name></person-group><article-title>Comparison of thyroid-stimulating hormone levels in adolescents with schizophrenia, bipolar disorder, unipolar depression, conduct disorders, and hyperkinetic disorders</article-title><source>Medicine (Baltimore)</source><year>2021</year><volume>100</volume><fpage>e28160</fpage><pub-id pub-id-type="pmid">34889284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000028160</pub-id><pub-id pub-id-type="pmcid">PMC8663859</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>B</given-names></name><name name-style="western"><surname>Retnakaran</surname><given-names>R</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Hao</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wen</surname><given-names>SW</given-names></name></person-group><article-title>Oxcarbazepine was associated with risks of newly developed hypothyroxinaemia and impaired central set point of thyroid homeostasis in schizophrenia patients</article-title><source>Br J Clin Pharmacol</source><year>2022</year><volume>88</volume><fpage>2297</fpage><lpage>2305</lpage><pub-id pub-id-type="pmid">34855997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.15163</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Retnakaran</surname><given-names>R</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Hao</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>D</given-names></name><name name-style="western"><surname>Wen</surname><given-names>SW</given-names></name></person-group><article-title>Impaired central set point of thyroid homeostasis during quetiapine treatment in the acute phase of schizophrenia</article-title><source>Schizophr Res</source><year>2022</year><volume>241</volume><fpage>244</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">35180663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.schres.2022.02.010</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petruzzelli</surname><given-names>MG</given-names></name><name name-style="western"><surname>Marzulli</surname><given-names>L</given-names></name><name name-style="western"><surname>Giannico</surname><given-names>OV</given-names></name><name name-style="western"><surname>Furente</surname><given-names>F</given-names></name><name name-style="western"><surname>Margari</surname><given-names>M</given-names></name><name name-style="western"><surname>Matera</surname><given-names>E</given-names></name><name name-style="western"><surname>Margari</surname><given-names>F</given-names></name></person-group><article-title>Glucose Metabolism, Thyroid Function, and Prolactin Level in Adolescent Patients With First Episode of Schizophrenia and Affective Disorders</article-title><source>Front Psychiatry</source><year>2020</year><volume>11</volume><fpage>775</fpage><pub-id pub-id-type="pmid">32848941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2020.00775</pub-id><pub-id pub-id-type="pmcid">PMC7422423</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanif</surname><given-names>F</given-names></name><name name-style="western"><surname>Amir</surname><given-names>Q</given-names></name><name name-style="western"><surname>Washdev</surname><given-names>W</given-names></name></person-group><article-title>Effect of DIO2 Gene Polymorphism on Thyroid Hormone Levels and Its Correlation with the Severity of Schizophrenia in a Pakistani Population</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><fpage>1915</fpage><pub-id pub-id-type="pmid">38339190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25031915</pub-id><pub-id pub-id-type="pmcid">PMC10855673</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>TY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LC</given-names></name><name name-style="western"><surname>Li</surname><given-names>XP</given-names></name><name name-style="western"><surname>Li</surname><given-names>WH</given-names></name><name name-style="western"><surname>Xu</surname><given-names>SX</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>C</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>P</given-names></name><name name-style="western"><surname>Nie</surname><given-names>ZW</given-names></name><name name-style="western"><surname>Yang</surname><given-names>NY</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>HW</given-names></name><name name-style="western"><surname>Turecki</surname><given-names>G</given-names></name><name name-style="western"><surname>Xie</surname><given-names>XH</given-names></name></person-group><article-title>Elevated triglycerides and low triiodothyronine: Key risk factors for coronary artery calcification in patients with schizophrenia</article-title><source>Schizophr Res</source><year>2024</year><volume>264</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">38128342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.schres.2023.12.007</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>H</given-names></name><name name-style="western"><surname>Tao</surname><given-names>L</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Ji</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name></person-group><article-title>Functional Status of Hypothalamic-Pituitary-Thyroid and Hypothalamic-Pituitary-Adrenal Axes in Hospitalized Schizophrenics in Shanghai</article-title><source>Front Psychiatry</source><year>2020</year><volume>11</volume><fpage>65</fpage><pub-id pub-id-type="pmid">32174848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2020.00065</pub-id><pub-id pub-id-type="pmcid">PMC7056840</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>D</given-names></name><name name-style="western"><surname>Bing</surname><given-names>J</given-names></name><name name-style="western"><surname>Shan</surname><given-names>X</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Wen</surname><given-names>W</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Niu</surname><given-names>K</given-names></name><name name-style="western"><surname>Cui</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Retnakaran</surname><given-names>R</given-names></name><name name-style="western"><surname>Hao</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wen</surname><given-names>SW</given-names></name></person-group><article-title>Higher central set point of thyroid homeostasis in drug-na&#239;ve patients affected by first episode schizophrenia</article-title><source>Schizophr Res</source><year>2022</year><volume>250</volume><fpage>62</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">36368279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.schres.2022.10.022</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melamed</surname><given-names>SB</given-names></name><name name-style="western"><surname>Farfel</surname><given-names>A</given-names></name><name name-style="western"><surname>Gur</surname><given-names>S</given-names></name><name name-style="western"><surname>Krivoy</surname><given-names>A</given-names></name><name name-style="western"><surname>Weizman</surname><given-names>S</given-names></name><name name-style="western"><surname>Matalon</surname><given-names>A</given-names></name><name name-style="western"><surname>Feldhamer</surname><given-names>I</given-names></name><name name-style="western"><surname>Hermesh</surname><given-names>H</given-names></name><name name-style="western"><surname>Weizman</surname><given-names>A</given-names></name><name name-style="western"><surname>Meyerovitch</surname><given-names>J</given-names></name></person-group><article-title>Thyroid function assessment before and after diagnosis of schizophrenia: A community-based study</article-title><source>Psychiatry Res</source><year>2020</year><volume>293</volume><fpage>113356</fpage><pub-id pub-id-type="pmid">32890863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psychres.2020.113356</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>She</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>TT</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Teng</surname><given-names>ZW</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name></person-group><article-title>Prolactin and Thyroid Stimulating Hormone (TSH) Levels and Sexual Dysfunction in Patients with Schizophrenia Treated with Conventional Antipsychotic Medication: A Cross-Sectional Study</article-title><source>Med Sci Monit</source><year>2018</year><volume>24</volume><fpage>9136</fpage><lpage>9143</lpage><pub-id pub-id-type="pmid">30554232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.913759</pub-id><pub-id pub-id-type="pmcid">PMC6319142</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>YF</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Fan</surname><given-names>FM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Fan</surname><given-names>HZ</given-names></name><name name-style="western"><surname>Cui</surname><given-names>YM</given-names></name><name name-style="western"><surname>Luo</surname><given-names>XG</given-names></name><name name-style="western"><surname>Tan</surname><given-names>SP</given-names></name><name name-style="western"><surname>Wang</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>FD</given-names></name><name name-style="western"><surname>Savransky</surname><given-names>A</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>M</given-names></name><name name-style="western"><surname>Goldwaser</surname><given-names>E</given-names></name><name name-style="western"><surname>Chiappelli</surname><given-names>J</given-names></name><name name-style="western"><surname>Rowland</surname><given-names>LM</given-names></name><name name-style="western"><surname>Kochunov</surname><given-names>P</given-names></name><name name-style="western"><surname>Tan</surname><given-names>YL</given-names></name><name name-style="western"><surname>Hong</surname><given-names>LE</given-names></name></person-group><article-title>Choroid Plexus Enlargement and Allostatic Load in Schizophrenia</article-title><source>Schizophr Bull</source><year>2020</year><volume>46</volume><fpage>722</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">31603232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/schbul/sbz100</pub-id><pub-id pub-id-type="pmcid">PMC7147577</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>GM</given-names></name><name name-style="western"><surname>Leung</surname><given-names>MTY</given-names></name><name name-style="western"><surname>Man</surname><given-names>KKC</given-names></name><name name-style="western"><surname>Leung</surname><given-names>WC</given-names></name><name name-style="western"><surname>Ip</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>GHY</given-names></name><name name-style="western"><surname>Wong</surname><given-names>ICK</given-names></name><name name-style="western"><surname>Kung</surname><given-names>AWC</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>CL</given-names></name></person-group><article-title>Maternal Thyroid Dysfunction During Pregnancy and the Risk of Adverse Outcomes in the Offspring: A Systematic Review and Meta-Analysis</article-title><source>J Clin Endocrinol Metab</source><year>2020</year><volume>105</volume><fpage>dgaa555</fpage><pub-id pub-id-type="pmid">32810262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgaa555</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability"><title>Data sharing statement</title><p>The data related to this paper can be obtained from the author on reasonable grounds.</p></sec></back></article></pmc-articleset>